Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study

PURPOSE: MLN8237, a selective small-molecule inhibitor of Aurora kinase A, has activity in a broad range of preclinical pediatric cancer models. We conducted a phase I trial in children with refractory/recurrent solid tumors to define the maximum-tolerated dose, toxicities, and pharmacokinetic prope...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Mossé, Yael P., Lipsitz, Emily, Fox, Elizabeth, Teachey, David T., Maris, John M., Weigel, Brenda, Adamson, Peter C., Ingle, Mark A., Ahern, Charlotte H., Blaney, Susan M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4008248/
https://ncbi.nlm.nih.gov/pubmed/22988055
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-3251
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados